Skip to main content

Table 1 Clinical characteristics of all included patients

From: Fecal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease patients with irritable bowel syndrome-type symptoms

  Control IBS CDR-IBS +  CDR-IBS- UCR-IBS +  UCR-IBS-
n 18 34 10 15 10 10
Age, mean ± SD, yr 37.9 ± 8.3 42.9 ± 14.0 30.9 ± 13.9 29.8 ± 10.5 37.1 ± 13.1 42.4 ± 12.7
Sex, male/female 10/5 13/21 5/5 11/4 8/2 8/2
Disease duration, median (range)   12(6–240) 24(12–60) 24(10–120) 27(12–120) 27(9–120)
Montreal A (Age of onset, yr), n (%)       
A1 (< 16)    0 1(6.7)   
A2 (17 ~ 40)    8(80) 12(80)   
A3 (> 40)    2 (20) 2(13.3)   
Montreal A (Location), n (%)       
L1 (ileal)    3(30) 5(33.3)   
L2 (colonic)    4(40) 3(20)   
L3 (ileocolonic)    3(30) 7(46.7)   
L4 (upper gastrointestinal tract)    0 0   
Montreal B (Behavior), n (%)       
B1 (nonstricturing, nonpenetrating)    9(90) 13(86.7)   
B2 (stricturing)    1(10) 1(6.7)   
B3 (penetrating)    0 1(6.7)   
Montreal E, n (%)       
E1 (ulceration proctitis)      3(30) 3(30)
E2 (left-sided ulceration colitis)      3(30) 4(40)
E2 (extensive ulceration colitis)      4(40) 3(30)
Therapy, n (%)       
5-ASA    2(20) 1(6.7) 8(80) 7(70)
Azathioprine    3(30) 2(13.3) 0(0) 0(0)
Steroids    0(0) 0(0) 2(20) 3(30)
Infliximab    5(50) 11(73.3) 0(0) 0(0)
Nutritional treatment    1(10) 2(13.3) 0(0) 0(0)
  1. CD: Crohn’s disease, CDR: Crohn’s disease in remission, CDR-IBS + : CDR with IBS-type symptoms, CDR-IBS-: CDR without IBS-type symptoms. UC: ulcerative colitis, UCR: ulcerative colitis in remission, UCR-IBS + : UCR with IBS-type symptoms, UCR-IBS-: UCR without IBS-type symptoms; SD: standard deviation; 5-ASA: 5-aminosalicylic acid